Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07301398

Development & Preliminary Validation of a Community Health Education Program

Construction and Preliminary Validation of a Community Health Education Program for Patients With Interstitial Lung Disease Based on Mobile Healthcare

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
92 (estimated)
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study analyzes the needs of patients regarding the content and form of home-based health education through interviews, and constructs a health education program tailored to these needs. A practical WeChat mini-program is developed to enable patients with interstitial lung disease to promptly access comprehensive health education information, consult about follow-up visits, and check test reports during their home care period, ultimately aiming to improve patients' quality of life and reduce medical consumption.

Detailed description

Interstitial Lung Disease (ILD) refers to a group of non-neoplastic and non-infectious diseases primarily affecting the alveolar walls, including lesions in the perialveolar tissues and adjacent supporting structures. It is characterized by progressive dyspnea, deteriorating lung function, and poor prognosis. In recent years, with the deterioration of air quality, the continuous advancement of diagnosis and treatment technologies, and physicians' deepened understanding of ILD, the diagnosis rate of ILD has been increasing year by year. As the detection rate rises, growing attention is paid to the survival and treatment of ILD patients. ILD patients often experience labored and rapid breathing, which limits their ability to perform daily activities. Low levels of physical function and vitality, coupled with severe dyspnea and fatigue, lead to a poor quality of life for these patients. Currently, clinical treatments can only control disease progression to a certain extent. Enhancing ILD patients' knowledge of their condition, encouraging active participation of patients and their families in nursing care, and improving patients' ability to monitor and manage their own health can effectively reduce the risk of infections, ensure the clinical efficacy of implemented treatment plans, and further alleviate patients' clinical symptoms. With societal progress and advances in medical technology, telemedicine has gradually been applied in clinical practice. Telemedicine interventions have proven beneficial for the home-based management and control of chronic diseases such as hypertension and diabetes. Therefore, integrating telemedicine with existing medical and nursing approaches for the home-based health guidance of ILD patients constitutes an innovative research with significant scientific value.

Conditions

Interventions

TypeNameDescription
BEHAVIORALThe use and guidance of the mini-programInterventions were conducted through routine health education, telephone follow-ups, and questionnaire surveys during reconsultations. Health education covered disease knowledge, medication guidance, rehabilitation guidance, dietary guidance, and psychological guidance. After discharge, patients were followed up by telephone or home visit once a month, and questionnaire data were collected during their reconsultations. The use of a mini-program was added with corresponding guidance: patients were instructed to proficiently use the mini-program's functions for accessing health education information, interacting with medical staff, and noting key points for questionnaire completion, and were advised to fill out the questionnaire monthly. Doctors and nurses were guided to skillfully use the mini-program to push health education-related knowledge to patients at irregular intervals, and medical staff were trained on the effective collection of questionnaire data and data statistics.

Timeline

Start date
2025-12-30
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2025-12-24
Last updated
2025-12-24

Source: ClinicalTrials.gov record NCT07301398. Inclusion in this directory is not an endorsement.